The PharmaFlow platform in combination with molecular analysis allows screening of agents that specifically target cellular mechanisms or pathways. Agents like inhibitors of tyrosine-kinase receptors (TKR), farnesyl-transferase inhibitors (FTI), mitogen activated protein kinase (MAPK), inhibitors mammalian target of rapamycin (mTOR) and AKT inhibitors; drugs that interfere with the cell cycle—ie, cyclin-dependent kinase (CDK) inhibitors and aurorakinase inhibitors; inhibitors of the unfolded protein response (UPR)—ie, heat-shock protein (HSP) inhibitors, proteasome inhibitors, or epigenetic agents. According to their specific mechanism of action, the appropriate readout is applied to each compound in our Native Environment Assays.